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Despite the success of abciximab in preventing ischemic events after percutaneous coronary
interventions, attempts to develop intravenous, small-molecule glycoprotein IIb/IIIa antag-
onists and diversify the clinical indications for these agents have produced varied results. The
30-day ischemic event reduction in the percutaneous coronary intervention trials has ranged
by over three-fold (16% to 56%) and is greater among the acute coronary syndrome trials. The
phase III trials exploring the role of oral glycoprotein IIb/IIIa inhibition have been
consistently disappointing, with evolving evidence of increased mortality. Mechanisms
contributing to these heterogeneous results may include normal variation in platelet or
receptor number, differences in receptor activity, interpatient variation in pharmacological
dose-response and the possibility of prothrombotic or nonglycoprotein IIb/IIIa effects.
Plausibility of “suboptimal” effect is suggested by several recent studies. Trials investigating
the role of intravenous small-molecule IIb/IIIa antagonists highlight the importance of
effective dosing. The increase in bleeding and mortality observed in the oral glycoprotein
IIb/IIIa studies indicate the consequences of suboptimal dosing on safety on one hand, while
raising the possibility of important prothrombotic, counterregulatory or other sudden cardiac
events. This article will undertake a review of the relevant platelet biology, discuss the
mechanisms that may contribute to suboptimal antiplatelet efficacy with these agents and
examine insights from the clinical trials supporting these concepts. (J Am Coll Cardiol 2000;
36:2028–35) © 2000 by the American College of Cardiology
Antagonists of the glycoprotein IIb/IIIa receptor block the
final common pathway for platelet aggregation (1), and
extensive research has brought three of these agents to
clinical practice. However, in contradistinction to the evi-
dence supporting cholesterol lowering and angiotensin-
converting enzyme inhibition therapy, the experience from
over 75,000 patients in glycoprotein IIb/IIIa trials is marked
by heterogeneity. Antibody-mediated glycoprotein IIb/IIIa
blockade during percutaneous coronary interventions (PCI)
has reduced 30-day ischemic outcomes by approximately
35% to 50% (2–4). In contrast, the clinical development of
more specific, small-molecule (peptide and peptidomimetic)
glycoprotein IIb/IIIa antagonists for PCI has been ham-
pered by the question of dose adequacy illustrated by less
consistent benefits (5–7). Moreover, as empiric therapy for
acute coronary syndromes (ACS), a therapeutic benefit
comparable with the PCI trials, appears to be confined to
those patients with evidence of myonecrosis (8,9) (i.e.,
troponin elevation) or undergoing early PCI (10). Of
greater concern is that attempts to extend specific receptor
blockade to chronic therapy with oral glycoprotein IIb/IIIa
antagonists have demonstrated an approximately 30% in-
crease in mortality (11).
The fundamental concept underpinning effective sup-
pression of ischemic events by these agents is an adequate
level of platelet glycoprotein IIb/IIIa receptor inhibition at
the time of threatened thrombotic occlusion or athero-
thrombotic embolization. The apparent divergence in effi-
cacy among various agents and in different clinical settings
may be explained by factors that compromise this level of
inhibition—variations in dose response, divergence of pa-
tient characteristics and evidenced (but not clearly defined)
prothrombotic mechanisms. In this article we consider how
these factors may contribute to the varied benefits observed
with intravenous agents (Fig. 1) and, more recently, oral
glycoprotein IIb/IIIa antagonists.
The aIIbb3 integrin (glycoprotein IIb/IIIa receptor).
The aIIbb3 integrin is found exclusively on platelets and
megakaryocytes, with 70,000 to 90,000 receptors expressed
on each platelet in the resting state (12). These het-
erodimeric molecules have large extracellular regions for
cation-facilitated ligand binding and small intracytoplasmic
tails mediating intracellular signal transduction. Several
extracellular domains have been characterized, such as the
KQAGDV binding site corresponding to the carboxyl-
terminal of the fibrinogen g-chain and a RGD binding site
corresponding Arg-Gly-Asp sequence found in many pro-
tein ligands including fibrinogen. Integrin binding affinity is
dynamic and dependent on the receptor’s conformational
status. In the resting state, affinity for fibrinogen binding is
low (13). Platelet agonists, via “inside-to-outside” signals
(14), trigger a change in the receptor’s structure, transform-
ing it to a high-affinity state (Fig. 2).
Conversely, receptor binding by fibrinogen, vWF and
synthetic compounds induce postoccupancy events known
as “outside-to-inside” signals. These signals modify mem-
brane fluidity, cytoskeletal activity (13), intracellular calcium
mobilization (15) and induce new receptor epitopes (16)
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(ligand-induced binding sites) and thereby link the glyco-
protein IIb/IIIa receptor to other important platelet func-
tions including granule secretion, P-selectin expression and
clot retraction. Platelet responses induced by outside-to-
inside signals are binding-site specific, such that ligand
binding at different sites within the aIIbb3 integrin induce
dissimilar responses (13). Therefore, the array of platelet
functions induced or inhibited by synthetic inhibitors may
be drug-specific. For example, while two agents may inhibit
platelet aggregation similarly, their effects on thrombin
generation (17) and P-selectin expression may be different
(18). Likewise, antagonist-initiated changes in aIIbb3 inte-
grin may, in fact, lead to postoccupancy events that favor
thrombosis (e.g., activating quiescent receptors). In short,
effective inhibition of platelet aggregation does not neces-
sarily equate with effective suppression of secretion or
platelet procoagulant activity.
The glycoprotein IIb/IIIa antagonists. Abciximab is a
monoclonal antibody fragment with high binding affinity
for the glycoprotein IIb/IIIa receptor in either the active or
inactive state (1) with additional activity against the avb3
integrin (19) and possibly MAC-1 (20). This agent has
almost no renal excretion, but transfer to unoccupied plate-
lets results in a gradual decline in antithrombotic effect (24
to 48 h for 50% recovery of ADP-induced aggregation).
Subsequent intravenous agents developed include eptifi-
batide (peptide-specific for the KGD motif and possibly the
fibrinogen g-chain), tirofiban and lamifiban (peptidomi-
metics of the RGD site). Compared with abciximab, these
small-molecule agents demonstrate exclusive specificity for
the aIIbb3 receptor, have less binding affinity, shorter
durations of biological effect (approximately 2 to 4 h)
beyond the administration period and predominantly un-
dergo renal excretion. However, like abciximab, binding is
not confined to activated receptors. The development of
prodrugs with RGD-specificity has provided oral agents,
including xemilofiban, orbofiban and sibrafiban, demon-
strating longer half-lives (approximately 4 to 11 h) and
predominantly renal excretion.
The correlation between percentage of receptor occu-
pancy and degree of platelet aggregation inhibition is at the
core of safe and effective glycoprotein IIb/IIIa inhibition.
Initial studies focused on percentage receptor occupancy,
correlating .80% receptor occupancy with .80% inhibi-
tion of ADP-induced aggregation (21). While targeting this
level of platelet inhibition has provided important reduc-
tions in ischemic events, heterogeneity of platelet-specific,
patient-specific and agent-specific factors may alter the
pharmacologic response and importantly affect clinical out-
come.
Factors potentially compromising the glycoprotein
IIb/IIIa inhibitor efficacy. Individual variability. Since
platelet thrombus formation is subject to the absolute
number of glycoprotein IIb/IIIa receptors available for
aggregation, individual variation in splenic size, platelet
count (22) and numbers of receptors per platelet may
influence dose response. For example, the normal range of
platelet count (approximately 150,000 to 400,000/mL) and
glycoprotein IIb/IIIa receptors per platelet (70,000 to
90,000) provide a four-fold range of total receptor number.
Variations in intrinsic platelet competence and receptor
number observed with age (23), gender (24) and diabetes
(25) may also affect dose response. At the molecular level,
the clinical impact of genetic aspects of the glycoprotein
IIb/IIIa receptor remains uncertain although recent mech-
anistic studies suggest that platelet outside-to-inside signal-
ing and response to platelet inhibitors are influenced by PlA
polymorphism (26,27).
Divergence in clinical effect may be accentuated by the
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dynamic nature of receptor expression and activity in re-
sponse to stimuli such as thrombin and fibrinogen. Throm-
bin increases platelet surface glycoprotein IIb/IIIa expres-
sion by approximately 50% (12), possibly supporting platelet
thrombosis despite antagonist activity, as evidenced by
persistent platelet aggregation during therapy with standard
abciximab doses in occasional patients with unstable angina
(28). Conversely, low fibrinogen levels, especially after
non-fibrin-specific fibrinolysis, may accentuate the anti-
thrombotic effects of glycoprotein IIb/IIIa receptor inhibi-
tion (29) and contribute to the approximately 40% increase
in bleeding events as observed in the Thrombolysis in
Myocardial Infarction-14 study (30).
Pharmacologic heterogeneity. Inter- and intraindividual
variation in the dose-response can also contribute to sub-
optimal effects. Pharmacokinetic studies have demonstrated
a subtherapeutic effect (,80% aggregation inhibition) after
bolus doses of glycoprotein IIb/IIIa inhibition in approxi-
mately 10% to 15% of patients undergoing PCI, with an
increased frequency among those presenting with ACS
(28,31,32). Failure of the maintenance infusion to sustain
platelet inhibition .280% has also been observed with each
intravenous agent, and intrapatient divergence appears to
increase with greater infusion duration (32,33).
Age, lean body mass and renal function also contribute to
pharmacologic heterogeneity, and these factors have been
shown to impact the efficacy and safety of glycoprotein
IIb/IIIa inhibition (34). Creatinine clearance is especially
relevant to the small-molecule inhibitors since their excre-
tion is almost solely by renal elimination. While most
clinical trials have excluded patients with creatinine .2.0 to
2.5 mg/dl (5–7), correlation between increased adverse
outcomes and reduced renal function has been observed
Figure 1. Overview of intravenous glycoprotein IIb/IIIa trials by pooled analysis, with respect to 30-day death or myocardial infarction. Relative risk ratios
for treatment with glycoprotein IIb/IIIa inhibitors as adjunctive therapy for percutaneous coronary intervention (PCI) and as empiric therapy for acute
coronary syndromes (ACS) with electrocardiographic evidence of ischemia.
Figure 2. Platelet glycoprotein IIb/IIIa structure and function. Het-
erodimeric structure with cation binding sites, RGD, KGD and
KQAGDV binding sites and intracellular tail mediating both inside-to-
outside and outside-to-inside signaling. Inside-out signals lead to increased
platelet glycoprotein IIb/IIIa receptor activation, while outside-in signals
increase ligand-induced binding site (LIBS) expression and cytoskeletal
responses.
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with lamifiban (35), sibrafiban (36) and orbofiban (37).
Interestingly, although increased bleeding events might
be expected, increased thrombotic outcomes have also
been observed. Despite the importance of renal function,
the recently completed Platelet IIb/IIIa Antagonism for
the Reduction of Acute Coronary Syndrome Events in a
Global Organization Network (PARAGON) B and Sibra-
fiban Versus Aspirin to Yield Maximum Protection From
Ischemic Heart Events Post Acute Coronary Syndromes
(SYMPHONY) trials, which respectively dosed intravenous
lamifiban and oral sibrafiban according to creatinine clear-
ance, did not show improved clinical outcomes relative to
previous fixed-dosing trials (38).
Prothrombotic and toxic mechanisms. Of perhaps greater
concern is the possibility that these agents promote throm-
botic events (partial agonist activity). While providing
potent antagonism of fibrinogen binding, their capacity to
prevent platelet secretion is not ensured and, in some
circumstances, may actually be enhanced. Since binding of
these antagonists is not confined to high-affinity receptors,
binding and stimulation of quiescent receptors may be
counterproductive. Peter et al. (39) have demonstrated
antagonist-induced receptor activation with both antibody-
fragment and small-molecule glycoprotein IIb/IIIa inhibi-
tion, and, during trough periods or after drug discontinua-
tion, the platelets may be left more activated than before
therapy. These mechanisms may have greater consequence
with oral therapy since plasma levels recurrently fall between
doses. Demonstrating this, Holmes et al. (40) reported
potentiation of platelet P-selectin expression in 15 patients
receiving orbofiban for 14 days (40). Enhanced activation
and recruitment of circulating platelets may also explain the
association between thrombotic events and thrombocytope-
nia observed in several studies (41,42). Ligand induced
binding sites expression also occurs (16,39,43), possibly
providing neoepitopes for immune-mediated platelet clear-
ance, while promotion of leukocyte-platelet aggregates has
also been reported with small-molecule antagonists (44).
Another intriguing mechanism that may contribute to
the varied benefit reported among trials is the finding that
RGD peptides can induce cardiomyocyte apoptosis (45).
Caspase-3 is a central enzyme of cellular apoptosis.
Procaspase-3, the precursor of the active molecule, contains
RGD-binding motifs adjacent to sites of processing re-
quired for activation. Time and dose-dependent increases in
caspase-3 activity and apoptosis have been reported with
prolonged incubation with the RGD peptides, xemilofiban
and orbofiban, but not with eptifibatide (KGD peptide) or
abciximab (Fig. 3). Furthermore, these effects on apoptosis
appear augmented in hypoxic conditions and may explain
some of the adverse-outcome observations made in the oral
glycoprotein IIb/IIIa trials (46).
Insights and questions from clinical trials. PCI. As ad-
junctive therapy for PCI, the primary objective of the
randomized trials with intravenous glycoprotein IIb/IIIa
inhibitors was to reduce a 30-day ischemic composite end
point (death, MI and urgent revascularization). While
substantial benefits have been reported in many trials,
significant reductions in ischemic end points have not been
uniformly observed, with relative risk reductions ranging by
over three-fold, from 16% to 56% (2–7,10,47–49). Of the
17,200 patients enrolled in large-scale studies (2–7,10,47–
49), the most compelling support for glycoprotein IIb/IIIa
therapy and the largest dataset (n 5 9,038) comes from the
abciximab trials. Collectively, these trials underscore several
aspects of antibody-mediated glycoprotein IIb/IIIa inhibi-
tion: 1) a clinically important reduction (approximately
40%) in early (30-day) ischemic events; 2) sustained benefits
at long-term (one-year) follow-up (2–4,50) and 3) benefits
extending similarly to all interventional devices, lesion
complexities (51) and patient acuities (3,4).
Not all aspects of the early abciximab data are consistent,
however. Some differences among the 30-day primary end
Figure 3. Increased apoptosis activity with oral RGD glycoprotein IIb/IIIa inhibitors. (A) Time dependent increase in apoptosis in rat neonatal
cardiomyocytes over 24 to 72 h. (B) Dose-dependent increase in apoptosis in rat neonatal cardiomyocytes observed with low-dose (3 mM), moderate-dose
(10 mM) and high-dose (30 mM) of orbofiban or xemilofiban. *p , 0.01; †p , 0.001. Reproduced with permission from Adderley et al (46).
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point reductions are evident, bringing into question the
timing of PCI and the optimal duration of the postproce-
dural drug infusion. In particular, the c7E3 FAB Anti-
platelet Therapy in Unstable Refractory Angina trial
(CAPTURE) reported a relative risk reduction in death,
myocardial infarction (MI) and urgent revascularization of
23% (p 5 0.012) using 18 to 24 h of preprocedural
abciximab but only a 1-h postprocedural infusion. In com-
parison, a 35% (p 5 0.008), 56% (p , 0.001) and 51% (p ,
0.001) reduction in the same end point was seen in the
Evaluation of c7E3 for the Prevention of Ischemic Com-
plications trial (EPIC), Evaluation in Percutaneous Trans-
luminal Coronary Angioplasty to Improve Long-term Out-
come With Abciximab Glycoprotein IIb/IIIa Blockade
(EPILOG) and Evaluation of IIb/IIIa Platelet Inhibitor for
Stenting (EPISTENT), respectively, employing a 12-h
postprocedural infusion. This distinction is consistent with
the evidence of subtherapeutic inhibition in up to 10% to
15% of patients after .28 to 12 h of abciximab infusion
(32,52) (Fig. 4) and underscores the value of “adequate”
inhibition during and after PCI. Thus, compared with the
EPI-trials, not only were CAPTURE patients’ platelets
more likely to be under 80% inhibited at the time of PCI,
but they also returned to normal function sooner after PCI.
Another seeming inconsistency is the reduction in clinical
restenosis by abciximab, which is suggested by lower rates of
target-vessel revascularization at six months in EPIC (26%
reduction, p 5 0.007) (3) and in the diabetic patients of
EPISTENT (51% reduction, p 5 0.002) (4). This reduc-
tion in restenosis has not been confirmed in other abciximab
trials and angiographic studies (53).
The clinical trial results with small-molecule glycoprotein
IIb/IIIa antagonists in PCI are varied and reinforce the
importance of adequate drug dosing. The Integrelin to
Manage Platelet Aggregation To Combat Coronary
Thrombosis-II trial (IMPACT II) (48), the initial PCI
study of eptifibatide, demonstrated a relative risk reduction
in death, MI or urgent revascularization at 30 days of 17%
(p 5 0.08). There was no significant reduction in target-
vessel revascularization or overall benefit at six months.
Reassessment of the dose found that reduction of the serum
calcium levels by EDTA (sample anticoagulant) lowered
fibrinogen-binding affinity and facilitated eptifibatide bind-
ing. Therefore, the percentage inhibition of platelet aggre-
gation for these doses (135 mg/kg bolus 1 0.5 mg/kg or
0.75 mg/kg infusion) was estimated to be only 40 to 50%
(roughly half the planned target level) (54). Patients under-
going PCI in the PURSUIT trial, with a higher eptifibatide
dose (180 mg/kg bolus 1 2.0 mg/kg infusion), experienced
a 31% (p 5 0.001) relative risk reduction in death or MI at
30 days (55). Likewise, a 43% (p 5 0.0017) reduction in the
same end point at 48 h has been preliminarily reported in
the Enhanced Suppression of the Platelet Glycoprotein
IIb/IIIa Receptor Using Integrelin Therapy trial (ESPRIT),
using a high-dose double-bolus and infusion regimen
(180 mg/kg bolus 1 2.0 mg/kg infusion 1 a second
180 mg/kg bolus after 10 min). Whether these dose in-
creases will provide durable benefit and long-term mortality
reductions as observed in EPISTENT awaits follow-up.
For now, further support for the dose-benefit gradient
comes from the 55% relative risk reduction in major adverse
cardiac events with platelet inhibition .95% at 10 min after
glycoprotein IIb/IIIa inhibitor bolus (p 5 0.006) observed
in the recent GOLD (Au-Assessing Ultegra) study (56).
These findings each highlight the fact that the optimal level
of platelet inhibition at the time of PCI is still incompletely
defined although a greater understanding of this issue has
been enabled by the advent of rapid platelet function testing
(57).
Issues of adequate dosing also cloud the experience with
tirofiban in PCI. The Randomized Efficacy Study of Tiro-
fiban for Outcomes and Restenosis trial (RESTORE)
demonstrated a 24% (p 5 0.052) reduction in 30-day death
MI, urgent revascularization and bailout stenting using
EPIC end point definitions (47). However, initial dose-
defining studies with tirofiban used 5 mM ADP-induced
platelet aggregation compared with 20 mM ADP used in
both abciximab and eptifibatide dose-defining studies.
Therefore, efficacy of this dose may not be comparable with
that of abciximab or eptifibatide in the face of clinically
relevant stimuli, as evidenced by a small direct-comparison
study (33). Relative clinical efficacy of this agent is even
more difficult to assess since this trial collected and adjudi-
cated creatine-kinase data only for patients with suspected
ischemic events. True comparative data awaits the results of
Figure 4. Divergence in platelet inhibition with abciximab with increasing
time. Divergence in platelet inhibition with increasing infusion duration
(52). Late variation in platelet inhibition may contribute to increased
periprocedural events as seen in CAPTURE when compared with EPIC,
EPILOG and EPISTENT. CAPTURE 5 C7E3 FAB Anti Platelet
Therapy in Unstable Refractory Angina; EPIC 5 Evaluation of c7E3 for
the Prevention of Ischemic Complications; EPILOG 5 Evaluation in
PTCA to Improve Long-term Outcome with Abciximab GP IIb/IIIa
blockade; EPISTENT 5 Evaluation of IIb/IIIa Platelet Inhibitor for
Stenting.
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the ongoing Do Tirofiban And Reopro Give Similar Effi-
cacy Outcomes Trial (TARGET), a randomized double-
blinded, double-dummy trial comparing tirofiban with ab-
ciximab in approximately 5,000 patients undergoing
coronary stenting.
ACS. Contrasting the substantial benefits experienced by
ACS patients within the PCI trials, integration of glyco-
protein IIb/IIIa antagonist therapy into the empiric man-
agement of ACS has observed a lesser magnitude of effect.
Collectively, with over 24,000 patients studied, the ACS
trials demonstrate an approximately 12% relative risk reduc-
tion in 30-day death or MI. However, when considered
individually, these trials report risk reductions ranging from
8% to 27% (5–7). Heterogeneity in these results may stem
from the inherent diversity of patient acuity and the uncer-
tain timing of thrombo-occlusive events within these pop-
ulations. The “timing of injury” concurrent with the period
of maximal platelet inhibition distinguishes the PCI trials
from the trials of glycoprotein IIb/IIIa inhibition therapy in
ACS patients. While the precise time, and at least to some
extent, the degree of vessel injury are known for patients
undergoing PCI, these factors are far less predictable in
patients considered at risk for spontaneous coronary
events. Thus, when PCI is undertaken at the time of
greater and more consistent platelet inhibition (i.e., early
in the treatment period), more substantial benefits may be
provided. This is evidenced by the 31%, 35% and 42%
relative risk reductions in 30-day death or MI observed in
patients undergoing early PCI in the PURSUIT study (55),
PARAGON B and Platelet Receptor Inhibition in Isch-
emic Syndrome Management in Patients Limited by
Unstable Signs and Symptoms trial (PRISM PLUS) (6),
respectively. These outcome reductions are greater than the
6%, 7% and 12% reductions in the same end point for those
patients not undergoing PCI in the respective trials.
Likewise, within the ACS population a marked hetero-
geneity in patient acuity occurs. While early PCI “localizes”
the time of injury, evidence of myonecrosis “defines” the
population at greatest risk for which the early institution of
glycoprotein IIb/IIIa therapy provides incremental benefit
over aspirin and heparin alone (Fig. 1). Validation of
this concept comes from the impressive reductions in death
or MI of 42% (p 5 0.018), 67% (p , 0.001) and 70%
(p 5 0.002) observed in the troponin positive patients of
PARAGON B, Platelet Receptor Inhibition in Ischemic
Syndrome Management trial (PRISM) (9) and CAPTURE
(8), respectively, many of whom underwent early PCI. In
short, clinically important reductions in ischemic events can
be expected when therapeutic glycoprotein IIb/IIa inhibi-
tion and the time of increased risk correspond.
Additional questions have been raised by the ACS trial
experience. Treating patients with very high levels of gly-
coprotein IIb/IIIa therapy has not consistently had favorable
outcome, with increased ischemic events, bleeding events or
both seen with several small-molecule antagonists (6). The
effect of concurrent heparin therapy in ACS patients adds a
further level of complexity. Increased adverse events ob-
served in the absence of concurrent heparin in some trials
(6,58) provide support for the clinical relevance of differ-
ences in thrombin inhibition documented among the
agents. These observations may also suggest the possibility
of important prothrombotic mechanisms, especially consid-
ering the oral glycoprotein IIb/IIIa experience.
The lack of benefit with oral glycoprotein IIb/IIIa
inhibition. Despite clinical trial experience with over
33,000 patients, variations in patient populations and study
designs and the study of three different oral glycoprotein
IIb/IIIa agents (sibrafiban [38], xemilofiban [59] and orbo-
fiban [37]), no reduction in ischemic events with these drugs
is evident. Moreover, trends towards an increased mortality
with the oral glycoprotein IIb/IIIa antagonists were ob-
served in each trial and are statistically significant for both
the Orbofiban in Patients With Unstable Coronary Syn-
dromes Thrombolysis In Myocardial Infarction 16 trial
(OPUS-TIMI 16) trial (37) and the second SYMPHONY
study (60). In keeping with the evidence of increased
P-selectin expression with orbofiban (40), analysis of the
cause of death in OPUS-TIMI 16 revealed an excess of
thrombotic events. Pooled analysis of the oral glycoprotein
IIb/IIIa inhibitor trials shows a 33% increase in mortality
(p 5 0.002) with long-term follow-up (11). Bleeding rates
were increased in all active treatment arms attesting to the
antiplatelet efficacy of these agents at the doses studied.
This stark disparity between the intravenous and oral
glycoprotein IIb/IIIa antagonist experience is perplexing
and is not reconciled by subtherapeutic dosing alone.
While the lack of sustained platelet inhibition between
doses is an obvious limitation of oral therapy, suboptimal
plasma levels cannot account for the results from the second
SYMPHONY trial where the highest mortality rate was
observed with high-dose sibrafiban. Nor does a dependence
of concurrent aspirin therapy fully explain these findings
since increased mortality was observed in the OPUS
TIMI-16 trial and the low-dose sibrafiban arm of the
second SYMPHONY trial, both of which included concur-
rent aspirin. Considered in combination with the phase II
trial experience (36,61–63), these data lend strong support
to the existence of clinically relevant prothrombotic mech-
anisms. Alternatively, the increased mortality observed
raises the possibility of toxic mechanisms, such as the effect
on ischemic apoptosis recently reported with RGD peptides
(45,46). Confirmation of the mechanisms involved in these
adverse events may enable the design of agents with im-
proved profiles.
Conclusions. Unquestionably, intravenous platelet glyco-
protein IIb/IIIa inhibition has proven to be an important,
clinically effective adjunct therapy during PCI and in the
management of ACS. This benefit is most apparent in those
patients with ACS with evidence of troponin elevation or
who are undergoing early PCI (Fig. 1). However, adverse
outcomes among treated patients persist, and heterogeneity
among the clinical trials is marked. Current weight-based
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dosing strategies do not adequately account for diversity in
platelet and patient-related factors, and the potential for
bleeding or triggering prothrombotic or toxic mechanisms
are increasingly being appreciated. These issues are high-
lighted by the difficulties in establishing a clear dose-
response relationship and suggest that greater benefits may
be achieved with more patient-specific dosing. Potential
prothrombotic effects and the dependence on concurrent
antithrombin therapy will require further clarification.
Rapid platelet function testing may help define a safe and
effective level of glycoprotein IIb/IIIa inhibition and allow
the optimization of doses in all patients. Likewise, ongoing
head-to-head trials comparing agents will provide impor-
tant new insights into the extent of class effect and relevance
of the various ancillary actions of the glycoprotein IIb/IIIa
inhibitors.
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